Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Fennec Pharmaceuticals Has Also Been Granted A CMS Permanent Product-Specific Reimbursement J-code (J0208) For Pedmark Effective April 1, 2023

https://www.cms.gov/files/document/2022-hcpcs-application-summary-quarter-4-2022-drugs-and-biologicals-updated-02/01/2023.pdf
byHappy Mohamed
February 13, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

https://www.cms.gov/files/document/2022-hcpcs-application-summary-quarter-4-2022-drugs-and-biologicals-updated-02/01/2023.pdf

Image

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Bristol Myers’ Antitrust Allegations: Lawsuit Over Alleged Patent Deception For Blood Cancer Drug

By Vandana Singh
September 7, 10:03 AM
Bristol Myers Squibb Co (NYSE: BMY) faces fresh allegations in a recent lawsuit, accused of employing deceptive patents and illicit strategies to preserve its dominant position in the blood cancer drug market with Pomalyst (pomalidomide) long after it should have faced competition from generic alternative

BMY